The AJMC® Immuno-Oncology compendium is a comprehensive resource for clinical news and expert insights for treatments that utilize the body's immune system to fight cancer, such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapies.

Myeloid Cells Hold Promise as Cancer Immunotherapy Targets, Review Says

September 17th 2022, 12:30pm


The review highlights current strategies for myeloid cell targeting and novel agents targeting myeloid cells for cancer treatment.

Neurofilament Light Chain Levels May Indicate Risk of CAR T–Related Neurotoxicity

September 7th 2022, 3:31pm


A significant portion of patients who receive chimeric antigen receptor (CAR) T-cell therapy experience immune effector cell–associated neurotoxicity syndrome, and this recent study suggests neurofilament light chain protein levels may hold promise as a biomarker to identify at-risk patients.

Which Chemo-IO Combo Is Optimal in First-line Esophageal Cancer?

September 2nd 2022, 8:19pm


The review of 5 phase 3 randomized controlled trials found that overall, the combination treatments improved survival outcomes while eliciting more, but manageable, side effects.

Contributor: Replacing White Bagging Mandates With Market Competition Will Improve Patient Outcome

August 30th 2022, 2:28pm


Wayne Winegarden, PhD, of the Pacific Research Institute, explains the harm that white bagging policies cause health systems and how replacing them with new measures to boost market competition could help patients.

CAR T-Cell Therapy Outcomes Likely Not Influenced by Race/Ethnicity, Obesity

August 21st 2022, 11:47am


Researchers studied data from 5 phase 1 studies that took place between 2012 and 2021, comprising 139 infusions among patients with B-cell acute lymphoblastic leukemia who received chimeric antigen receptor (CAR) T-cell treatment.

Targeted Treatment for Breast Cancer Explored in New Study

August 14th 2022, 12:15pm


Despite advances made against the disease, researchers note that breast cancer still remains a top cause of cancer-related mortality in women around the world.

CAR T Outcomes Not Significantly Affected by rrDLBCL Subgroup

August 9th 2022, 10:07pm


With 40% of patients with diffuse large B-cell lymphoma experiencing relapsed or refractory disease (rrDLBCL), researchers highlighted the promise of chimeric antigen receptor (CAR) T-cell therapy for these patients.

Three CAR T-Cell Trials, 2 Outcomes, for Second-line LBCL Therapy

August 4th 2022, 11:19pm


Both the ZUMA-7 trial for axicabtagene ciloleucel—approved for second-line treatment earlier this year—and the TRANSFORM trial for lisocabtagene maraleucel showed significant improvement over standard of care for large B cell lymphoma (LBCL), while the BELINDA trial for tisagenlecleucel did not.

Dr Amila Patel Highlights Findings on Disparities in Immunotherapy Delivery

July 29th 2022, 4:54pm


Data presented at the American Society of Clinical Oncology annual meeting found non-White patients are less likely to receive immunotherapy for head and neck cancer, said Amila Patel, PharmD, chief clinical officer, Navigating Cancer.

Fungal Infections Rarer, Linked With Worse Prognosis in Patients Receiving CAR T-Cell Therapy

July 25th 2022, 10:25pm


Overall, infections occurred in 18.42% of cases and typically occurred within the first month, significantly dropping from then on.